Section Arrow
CGON.NASDAQ
- CG Oncology
Quotes are at least 15-min delayed:2026/02/19 19:30 EST
After Hours
Last
 57.09
+0.67 (+1.19%)
Bid
34.79
Ask
56.48
High 57.09 
Low 56.42 
Volume 4.53K 
Regular Hours (Closed)
Last
 56.42
+1.21 (+2.19%)
Day High 
56.85 
Prev. Close
55.21 
1-M High
57.88 
Volume 
637.65K 
Bid
34.79
Ask
56.48
Day Low
54.24 
Open
54.43 
1-M Low
48.51 
Market Cap 
4.56B 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 52.15 
20-SMA 53.14 
50-SMA 47.47 
52-W High 57.88 
52-W Low 14.8 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-2.05/-1.41
Enterprise Value
4.56B
Balance Sheet
Book Value Per Share
8.32
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
1.14M
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
TOVXTheriva Biologics Inc0.1967+0.0047+2.45%0.09PE
After Hours 0.188 -0.0087 -4.42%
IBRXImmunityBio8.61+0.07+0.82%-- 
After Hours 8.46 -0.15 -1.74%
DRMADermata Therapeutics Inc1.93+0.65+50.78%0.08PE
After Hours 1.81 -0.12 -6.22%
QNCXQuince Therapeutics0.1622-0.0158-8.88%-- 
After Hours 0.1616 -0.0006 -0.37%
LIMNLiminatus Pharma Inc0.2383-0.0066-2.69%-- 
After Hours 0.235 -0.0033 -1.38%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.